Physical Therapists in Osceola, IA Accepting Medicare
6 Physical Therapists found. Showing 1 - 6
 Sadie Robb, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 W Mclane St, Osceola, IA 50213 Phone: 641-342-1470 Fax: 641-342-1219 |
 Eric Gross, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 S Fillmore St, Osceola, IA 50213 Phone: 641-342-5340 |
Gabriel Dubberke Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 W Mclane St, Osceola, IA 50213 Phone: 641-342-1470 |
Brady Buchheit, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 W Mclane St, Osceola, IA 50213 Phone: 641-342-1470 |
Dillon Anderson, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 109 W Mclane St, Osceola, IA 50213 Phone: 641-342-1470 |
 Professional Physical Therapy Services, Inc. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 123 E Jefferson St, Osceola, IA 50213 Phone: 641-342-1470 Fax: 641-342-1219 |
News Archive
Forgetful? Look at the time
An interesting new paper describes the discovery of a gene in mice that affects the degree of memory recall at various times of day. They found that this gene makes mice most forgetful at the time immediately before they wake.
New report highlights increasing cost of caring for people with Alzheimer's and dementia
The national cost of caring for those with Alzheimer's and dementia is estimated to be $259 billion this year, according to a new report from the Alzheimer's Association.
New procedure used for breast cancer surgery
Breast cancer surgeons and radiation oncologists at St. Joseph Hospital in Orange performed a new procedure combining removal of a patient's breast tumor with the power of electron beam radiation in the operating room.
UNMCC to investigate R-ketorolac use against ovarian cancer cells
Most drugs take ten years-and frequently, more-to go from concept to FDA approval. One way to reduce this time investment is to look for already-approved drugs that could be put to new uses. And that's just what Angela Wandinger-Ness, PhD, UNM Professor of Pathology, and Laurie Hudson, PhD, UNM Professor of Pharmaceutical Sciences, have done.
Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 4 days ago